Daratumumab

RED:

NICE TA573 - with bortezomib and dexamethasone for previously treated multiple myeloma. (Decision date - May 2019).
NICE TA763 - in combination for untreated multiple myeloma when a stem cell transplant is suitable. (Decision date - March 2022).
NICE TA783 - monotherapy for treating relapsed and refractory multiple myeloma. (Replaces NICE TA510). (Decision date - May 2022).
NICE TA897 - with bortezomib and dexamethasone for previously treated multiple myeloma. (Decision date - July 2023)
NICE TA917 - with lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitable. NHSE commissioned. (Decision date - November 2023)
NICE TA959 - in combination for treating newly diagnosed systemic amyloid light-chain amyloidosis. NHSE commissioned. (Decision date - April 2024)

DO NOT PRESCRIBE (DNP):

NICE TA454: daratumumab with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma. (Terminated appraisal). (Decision date - August 2017)
NICE TA726: Daratumumab with pomalidomide and dexamethasone for treating relapsed or refractory multiple myeloma. (Terminated appraisal). (Decision date - Oct 2021).
NICE TA771: Daratumumab with bortezomib, melphalan and prednisone for untreated multiple myeloma. (Terminated appraisal). (Decision date - March 2022).

NHS England drug. To be used in line with NHS England commissioning intentions.

1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)